DEM Bio is pioneering the next generation of immunotherapeutics designed to unleash macrophages and other myeloid effector cells to eliminate tumors by targeting novel ‘don’t eat me’ (DEM) and ‘eat me’ (EM) signals on cancer cells and macrophages. Our proprietary CHoMP™ platform (Co-culture with Human Myeloid Phagocytes) will be used to identify unexplored DEM and EM signals in a systematic and unbiased manner via inter-cellular CRISPR screening using tumor cells, primary macrophages, and other innate immune effector cells. DEM Bio was co-founded by the Longwood Fund and distinguished scientists Drs. Jonathan Weissman, Kipp Weiskopf, and Michael Bassik.

Our Team

MANAGEMENT

Christophe Quéva, PhD

CSO

Christophe Quéva, PhD

CSO

Christophe Quéva, PhD, joined DEM Bio in September 2022 as Chief Scientific Officer.  Prior to joining DEM Bio, Dr. Quéva was Chief Scientific Officer at Oncorus Inc., a publicly-traded, immuno-oncology clinical-stage company, where he was responsible for directing and advancing the company’s development program based on its next-generation immunotherapy platform of oncolytic viruses.

Dr. Quéva was also the Chief Scientific Officer at iTeos Therapeutics where his responsibilities included leading the generation of an innovative immuno-oncology portfolio of small molecule and antibody programs and overseeing the company’s translational medicine strategy for its A2A antagonist and TIGIT programs.

Before iTeos, he held successive senior positions at AstraZeneca, Amgen and Gilead Sciences where he led or supported drug discovery programs for oncology and inflammatory diseases, from target selection to commercial approval for small molecules and biologics.

A holder of one patent and widely published, Dr. Quéva trained as a post-doctoral fellow at the Fred Hutchinson Cancer Research Center in Seattle after receiving his PhD in Life and Health Sciences from the University of Lille, France.

John McCabe, MBA

CFO/COO

John McCabe, MBA

CFO/COO

Prior to DEM Bio, John McCabe served as Chief Financial Officer of Oncorus, Inc., a publicly-traded, immuno-oncology clinical-stage company from July 2019 to March 2022. Prior to Oncorus, Mr. McCabe held various positions of increasing responsibility at Flex Pharma, Inc., a clinical-stage, publicly-traded biotechnology company, from 2014 to July 2019, including most recently serving as its Chief Financial Officer. From 2013 to 2014, Mr. McCabe served as the Vice President and Chief Accounting Officer of ARIAD Pharmaceuticals, Inc., a publicly-traded global oncology company. From 2009 until 2013, he served as the Vice President and Corporate Controller of CRA International, Inc. (Charles River Associates), and from 2007 until 2009, he was Director, Strategic Business Unit Controller at Biogen Idec Inc.. Mr. McCabe holds an MBA from the University of Massachusetts at Amherst and a BS in accounting and a BS in management information systems from Babson College. Mr. McCabe is a Certified Public Accountant (inactive).

Loise Francisco, PhD

SVP, Head, Biology

Loise Francisco, PhD

SVP, Head, Biology

Dr. Francisco is the SVP and Head of Biology at DEM Biopharma. She is a pioneer in T cell immune checkpoints and dendritic cell biology, with over 22 years of immunology and immuno-oncology experience. Prior to joining DEM Biopharma, Dr. Francisco held various leadership positions at GSK (NYSE: GSK),  and Evelo Biosciences (NASDAQ: EVLO). At Evelo, she served as Vice President of Discovery and Oncology Research, where her role encompassed leading the preclinical discovery of novel targets in oncology through a successful Phase I/II clinical trial. At GSK Dr. Francisco was a Scientific Group Leader where she led a US and UK-based team developing a novel biologics program targeting innate immune responses.

Dr. Francisco completed her postdoctoral fellowship at Harvard Medical School in the Department of Immunology. As a member of Dr. Arlene Sharpe’s laboratory, she characterized the role of the PD-L1: PD-1 pathway in regulating T cells in autoimmunity and cancer, for which she is an author on several landmark papers and an inventor on early patents. Dr. Francisco earned her PhD in Immunology from Johns Hopkins University School of Medicine in Dr. Drew Pardoll’s laboratory and was co-mentored by Nobel Laureate, Dr. Ralph Steinman, at the Rockefeller University. Dr. Francisco previously earned a BS in Molecular Cell Biology and a BA in Psychology from the University of California, Berkeley.

Rob Hadfield, JD

General Counsel
General Counsel & Operating Partner,  Longwood Fund

Rob Hadfield, JD

General Counsel
General Counsel & Operating Partner,  Longwood Fund

Mr. Hadfield is the General Counsel and an Operating Partner of Longwood Fund, where he oversees all legal matters of the fund and assists with due diligence, new company formations and operations, and portfolio company management. Mr. Hadfield has extensive executive experience, having served as the General Counsel for two life science public companies, with oversight responsibilities of legal matters, intellectual property, business development, and administrative functions. Mr. Hadfield was previously the General Counsel of Ziopharm Oncology, Inc. and Flex Pharma, Inc., and Corporate Counsel at Kiva Systems, Inc., prior to its acquisition by Amazon. Mr. Hadfield spent seven years as an attorney in the business department of Cooley LLP, and began his career as a financial analyst in the health care investment banking group of Cowen Inc. Mr. Hadfield holds a J.D. from the Georgetown University Law Center and a BS degree in Finance from Providence College.

DIRECTORS

Jan Skvarka, PhD, MBA

Executive Chairman, DEM Bio

Jan Skvarka, PhD, MBA

Executive Chairman, DEM Bio

Dr. Skvarka is Executive Chairman and member of the Board of Directors of DEM Biopharma. Previously, he was the CEO of Trillium Therapeutics (Nasdaq: TRIL), a clinical-stage immuno-oncology company, where he led a highly successful, 360-degree business transformation that produced a leading CD47 drug candidate, and took the company from a $16M market capitalization to a $2.3B acquisition by Pfizer in two years. Before Trillium, Dr. Skvarka was the CEO of Tal Medical, a private clinical-stage neuromodulation company, and a leading partner in the healthcare practice of Bain & Company. In addition to DEM, Dr. Skvarka is Executive Chairman at GentiBio, a Tregs-focused cell therapy company. He holds an MBA from Harvard Business School and a PhD in Economics from the Economic University in Slovakia.

Christoph Westphal, MD, PhD

Founding CEO, Director, DEM Bio
Founding Partner, Longwood Fund

Christoph Westphal, MD, PhD

Founding CEO, Director, DEM Bio
Founding Partner, Longwood Fund
Lead Investor/CEO/Founder: ALNY, MNTA, XLRN, SIRT, VSTM, TCRX, Immunitas, ImmuneID

Dr. Westphal is co-founder and General Partner of Longwood Fund and has spent 20 years as a biotech CEO, entrepreneur, and investor. Dr. Westphal has been the co-founder, CEO, and lead investor of seven biotechnology companies that have completed initial public offerings (IPOs) and created sustained market value of over $40 billion and have developed and received FDA approval for over 10 important drugs. These include: Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA, acquired by J&J in 2020), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Acceleron Pharma, Inc. (NASDAQ: XLRN, acquired by Merck in 2021), Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT, acquired by GSK in 2008), Verastem (NASDAQ: VSTM), and TScan Therapeutics (NASDAQ: TCRX). Dr. Westphal is also co-founder of Alnara Pharmaceuticals (acquired by Eli Lilly in 2010); co-founder/former CEO of DEM Bio Pharma, co-founder/Chair of ImmuneID; co-founder/former CEO/Chair of Immunitas Therapeutics; co-founder of Pyxis Oncology (NASDAQ: PYXS); and co-founder of Concert Pharmaceuticals (NASDAQ: CNCE). Companies founded by Dr. Westphal have created thousands of jobs in the Boston area.

Companies founded by Dr. Westphal and Longwood partners have founded over 20 biotech companies, received FDA approval for over 20 important drugs, including the first RNAi therapy; for currently incurable cancers; the largest-selling heparin in the United States; a therapy for MS; for Beta Thalassemia and Myelodysplastic Syndrome; and several experimental medicines: for cystic fibrosis (phase 3); for serious inflammatory disorders (phase 2), and created sustained market caps of over $100 billion.

Dr. Westphal earned his M.D. from Harvard Medical School and Ph.D. in genetics from Harvard University; and he graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University. Dr. Westphal has served or currently serves as a member or director of: the Boston Commercial Club, the Biotechnology Industry Organization’s (BIO) Emerging Companies Section Governing Board, the Board of Fellows of Harvard Medical School, and the Board of Trustees of the Boston Symphony Orchestra; he is also a member of the ownership group of the Boston Celtics. Dr. Westphal has been the lead or senior author on several patent applications and scientific papers in journals such as Cell, Nature, and Nature Genetics. Dr. Westphal has been featured on 60 Minutes with Morley Safer, CNN’s Vital Signs with Dr. Sanjay Gupta, an ABC News Special hosted by Barbara Walters, and as the subject of Fortune, New York Times, and Wall Street Journal cover articles. Dr. Westphal has generally avoided media interviews since 2010.

Dan Janney, MBA

Director, DEM Bio
Managing Partner, Alta Partners

Dan Janney, MBA

Director, DEM Bio
Managing Partner, Alta Partners

Mr. Janney is the Managing Partner of Alta Partners. Mr. Janney joined Alta Partners at its founding in 1996. He has nearly 25 years of successful early-stage investing experience in life sciences. Mr. Janney’s focus on working with talented entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of 35 companies. Prior to Alta, Mr. Janney was a senior investment banker at Montgomery Securities.

Mr. Janney is currently on the board of directors of several public and private companies, including Allakos (NASDAQ: ALLK), Be Biopharma, Curasen Therapeutics, ImmuneID, Krystal Biotech (NASDAQ: KYRS), Lassen Therapeutics, Novome Biotechnologies, and Prolacta Bioscience. In addition, he led Alta’s investments in Astex Pharmaceuticals (acquired by Supergen), Cellective (acquired by Medimmune), ChemGenex (ASX: CXS acquired by Cephalon), CoTherix (NASDAQ: CTRX acquired by Actellion), Definity Health (acquired by United Health), Dynavax (NASDAQ: DVAX), Endonetics (acquired by Medtronic), Esperion Therapeutics (NASDAQ: ESPR), Ilex Oncology (NASDAQ: ILXO acquired by Millennium Pharmaceuticals), InterMune (NASDAQ: ITMN acquired by Roche), LJL Biosystems (NASDAQ: LJLB acquired by Molecular Devices), Mako Surgical (NASDAQ: MAKO acquired by Stryker) and Triangle Pharmaceuticals (NASDAQ: VIRS acquired by Gilead).

Mr. Janney is a member of The President’s Council of the J. David Gladstone Institutes and the chair of the Board of Directors of the California Academy of Sciences. He also serves on the Board of Regents of Georgetown University. He holds a BA from Georgetown University and a MBA from the Anderson School at the University of California, Los Angeles.

Dylan Morris, PhD

Director, DEM Bio
Managing Director, Insight Partners

Dylan Morris, PhD

Director, DEM Bio
Managing Director, Insight Partners

Dr. Morris is a Managing Director at Insight. He joined the firm in 2021 to focus on investments in computational biology. Dr. Morris was previously a general partner at CRV, where he built the bioengineering practice, leading the firm’s investments in Dyno Therapeutics, Recursion Pharmaceuticals, and Plexium, among others. Prior to CRV, Dr. Morris invested at Innovation Endeavors, Eric Schmidt’s early stage venture capital firm, where he drove investments in companies operating at the intersection of data science and life science.

Before becoming an investor, Dr. Morris cofounded Integrated Plasmonics, a venture-backed point-of-care diagnostics startup. Prior to that, he conducted graduate research in biochemistry and molecular biophysics at Caltech, where he co-authored multiple peer-reviewed publications. Dr. Morris received his AB in Computer Science from Harvard University.

Marie-Claire Peakman, MRPharmS, PhD

Director, DEM Bio
Principal, Pfizer Ventures

Marie-Claire Peakman, MRPharmS, PhD

Director, DEM Bio
Principal, Pfizer Ventures

Dr. Peakman is a Principal on the Pfizer Ventures Team and an Executive Director in Emerging Science & Innovation at Pfizer. In her current role she has responsibility for investing in early-stage biotech companies and supporting them in advancing emerging science to deliver new medicines to patients. Dr. Peakman holds a B.Pharm.Hons. degree in Pharmacy and a PhD in Physiology & Pharmacology from the University of Nottingham U.K. She conducted postdoctoral work at Yale University in the department of Molecular Biophysics & Biochemistry and the department of Molecular Psychiatry. Dr. Peakman has been at Pfizer for 24 years holding various leadership positions supporting small molecule lead discovery. As part of her former responsibilities, Dr. Peakman founded and led the Primary Pharmacology Group for 13 years during which time they were responsible for the identification of nirmatrelvir (Paxlovid), abrocitinib (Cibinqo), danuglipron, ervogastat, clesacostat, ritlecitinib and additional small molecule therapeutics that are currently in the clinic. She was recognized as a PhRMA ‘We Work For Health’ Champion in 2018 and was a 2019 finalist for the CT Women of Innovation Award. She is a member of The Royal Pharmaceutical Society, Chair of the Board of Directors for United Way of Southeastern CT, on the Board of Trustees for Lawrence and Memorial Hospital and Treasurer on the Board of Directors for the Thames River Innovation Place. She is also currently the Executive Sponsor for the Pfizer Women’s Resource Group in CT.

Hiromichi Kimura, PhD

Director, DEM Bio
Investment Director, Astellas Venture Management

Hiromichi Kimura, PhD

Director, DEM Bio
Investment Director, Astellas Venture Management

Dr. Kimura has more than 20 years R&D experience. Dr. Kimura serves multi-dimensional R&D activities, especially Oncology as a PhD Scientist and Investor, Board Director/DEM Biopharma (Don’t Eat Me/Eat Me signals), NeoPhore (DNA Mismatch Repair), Stealth company (Spliceosome), and Board Observer (7 companies), Investor advisory board member of many venture capital funds across US, EU/UK and Asia, Academic appointments.

Before joining Astellas Venture Management in 2018, he served as Head of Alliance & Management Group in Drug discovery research at Astellas Pharma Inc. including Research leadership of post-merger integration of Biotech and Venture (Ganymed Pharmaceuticals, Ogeda, SA, Quethera, Ltd.). Dr. Kimura co-founded Kyoto University-Astellas incubator research station in Kyoto University. Dr. Kimura conducted drug discovery as Research Manager, Oncology research unit, Astellas Pharma Inc. and also led many global research collaborations with Crick institute and Beatson Institute, and MDACC etc. since he joined Astellas in 2014. Prior to Astellas, Dr. Kimura served as Research head, Head of Pharmacology in Oncology Drug Discovery Unit, Takeda Pharmaceutical Company, and Drug Discovery department in Millennium: Takeda Oncology Company. In this capacity of an officer with high responsibility, Dr. Kimura was responsible for drug discovery from early to late stage including innovative platform technologies at Japan facility as well as global drug discovery initiatives and generated first-in-class projects and programs. Dr Kimura also served the number of academic lectures with academic appointments. Prior to his tenure at Takeda, Dr. Kimura was dedicated to conducting basic research and developing Drug Discovery and Translational Research as a Senior Postdoc Research leader in St Jude Children’s Research Hospital (led by Dr. Tom Curran, FRS, currently Executive Director and Chief Scientific Officer of the Children’s Research Institute, Children’s Mercy Hospital), collaborated with Genentech (Dr. Fred de Savage, Vice President) and Curis (Dr. Lee Rubin, CSO, currently Professor at Harvard University). Achievements published are designated as the first invention of live animal pharmacokinetics/dynamics imaging system. The activity contributed the project to launching as Hedgehog antagonist, Vismodegib®.  Dr. Kimura is appointed a unique academic position in Japan top-tier graduate school program in the University of Tokyo since 2018. Dr. Kimura received a PhD with distinction in Epigenetics, Cellular Molecular Biology/Veterinary Medical Sciences from the University of Tokyo.

Nenad Grmusa

Director, DEM Bio
CEO, DEM Bio

Nenad Grmusa

Director, DEM Bio
CEO, DEM Bio

Nenad Grmusa, joined DEM Bio as Chief Executive Officer in September 2022. Prior to joining DEM Bio, Mr. Grmusa led the R&D Strategy and External Innovation group at Takeda. In this role, he oversaw all external research and development activities including strategic venture investments, academic alliances, R&D collaborations, and spinouts. He was also responsible for R&D Finance and Portfolio Strategy, innovative R&D business and venture investment models, and divestiture strategies for non-core assets.

Previously, Mr. Grmusa served as Head, Center for External Innovation and R&D Portfolio & Investment Strategy at Takeda, where he supported the Head of R&D in managing Takeda’s diverse pipeline from early discovery to commercial life cycle management. Mr. Grmusa has 20 years of experience in R&D finance, financial planning and analysis, and pharmaceutical portfolio management.

Prior to joining Takeda, Mr. Grmusa spent 10 years with Millennium Pharmaceuticals, Inc. in various financial planning and analytical roles with increasing responsibilities. While at Millennium, Mr. Grmusa directly engaged with R&D leaders and the Millennium management team on pipeline investment management and strategic corporate planning. Prior to Millennium, he spent 3 years in consulting with Boston Biomedical Consultants.

Mr. Grmusa holds an MA in International Economics and Finance from Brandeis University and a BS in Finance from West Virginia University.

Scientific Co-founders / Scientific Advisory Board

Jonathan Weissman, PhD

Scientific Co-founder & SAB Co-chair

Jonathan Weissman, PhD

Scientific Co-founder & SAB Co-chair

Dr. Weissman is a Professor of Biology at MIT, an investigator at the Howard Hughes Medical Institute, the Landon T. Clay Professor of Biology at the Whitehead Institute, and a member of the National Academy of Sciences. His research is focused on how cells ensure that proteins fold into their correct shape, as well as the role of protein misfolding in disease and normal physiology and building innovative tools for broadly exploring organizational principles of biological systems. These include ribosome profiling, which globally monitors protein translation, CRIPSRi/a for controlling the expression of human genes and rewiring the epigenome and lineage tracing tools, to record the history of cells.

Dr. Weissman has received several distinctions for his work including the Ira Herskowitz Award from the Genetic Society of America, the National Academy of Sciences Award for Scientific Discovery and the Raymond and Beverly Sackler International Prize in Biophysics. He received his PhD from the Massachusetts Institute of Technology.

Michael Bassik, PhD

Scientific Co-founder & SAB Co-chair

Michael Bassik, PhD

Scientific Co-founder & SAB Co-chair

Dr. Bassik is an Associate Professor in the Department of Genetics at Stanford University. His laboratory at Stanford focuses on development of CRISPR/Cas9 based systems for high-throughput screening by mutagenesis, single and pairwise gene perturbation, and application of these technologies to two major areas: (1) understanding mechanisms of cancer growth and drug resistance in order to find new therapeutic targets, and (2) mechanisms by which macrophages and other cells take up diverse materials by endocytosis and phagocytosis; these substrates range from bacteria, viruses, and cancer cells to drugs and protein toxins.

Kipp Weiskopf, MD, PhD

Scientific Co-founder & SAB Co-chair

Kipp Weiskopf, MD, PhD

Scientific Co-founder & SAB Co-chair

Dr. Weiskopf, M.D., Ph.D. is a Valhalla Fellow at Whitehead Institute for Biomedical Research in Cambridge, MA. He is a pioneer of macrophage-directed therapies and leads a research laboratory that studies novel macrophage and myeloid immune checkpoints for the treatment of cancer. As a physician-scientist, Dr. Weiskopf also maintains a clinical appointment at Dana-Farber Cancer Institute as a Hematology and Oncology fellow.

Dr. Weiskopf earned his medical and graduate degrees at Stanford University. As a member of Dr. Irving Weissman’s laboratory, he characterized the CD47/SIRPa interaction as an immune checkpoint that regulates macrophages in cancer. He engineered therapies that stimulate macrophages to attack tumors and showed these could be effective for many types of cancer. Dr. Weiskopf is an inventor on over 15 issued U.S. patents pertaining to macrophage-directed therapies. He co-founded ALX Oncology, a biotech company that is investigating macrophage-directed therapies in multiple Phase 1 and 2 trials for cancer, and serves on the company’s scientific advisory board. Other technology that Dr. Weiskopf invented has been licensed to Forty Seven, Inc. (acquired by Gilead).

Dr. Weiskopf completed his medical training in the Internal Medicine Residency Program at Brigham and Women’s Hospital and is board certified in Internal Medicine. He has previously been awarded a Winston Churchill Scholarship, the Harold M. Weintraub Graduate Student Award, first place in the Collegiate Inventors Competition, and the AACR-AstraZeneca Career Development Award for Physician-Scientists, in Honor of José Baselga. Dr. Weiskopf previously earned a B.A. from Amherst College and an M.Phil. in genetics from University of Cambridge.

Dian Yang, PhD

Scientific Co-founder

Dian Yang, PhD

Scientific Co-founder

Dr. Yang did his PhD with Drs. Monte Winslow and Julien Sage at Stanford, where he studied the epigenetic and genetic mechanisms of cancer metastasis. His PhD work was awarded the Denise A. Chan Outstanding Thesis Award in 2017.

Dr. Yang is currently a Damon Runyon Postdoctoral Fellow in Dr. Jonathan Weissman’s lab. His work on developing innovative approaches has brought new insights into tumor evolution and tumor-immune cell interaction. He has won several awards, including a Damon Runyon Jake Wetchler Award, and more recently, a Dale F. Frey Award for Breakthrough Scientists.

Roarke Kamber, PhD

Scientific Co-founder

Roarke Kamber, PhD

Scientific Co-founder

Dr. Kamber is a postdoctoral fellow in Michael Bassik’s laboratory in the Department of Genetics at Stanford University. He is the recipient of an NIH/NCI K99/R00 Pathway to Independence Award and a postdoctoral fellowship from the Jane Coffin Childs Memorial Fund for Medical Research. He conducted his PhD work as an NSF Graduate Research Fellow in the laboratory of Vladimir Denic at Harvard, investigating the regulation of damaged organelle elimination by autophagy, and received a BS with Honors in Biology from Stanford University. As a postdoc, he developed a CRISPR screening platform that uncovered several novel inter-cellular signaling axes that impede cancer cell clearance by macrophages. He has additionally co-developed methods for the unbiased prediction of uncharacterized gene functions. His work has been published in several peer-reviewed journals including Nature, Nature Genetics, eLife, and Molecular Cell.

Robert Uger, PhD

Chief Scientific Advisor, SAB

Robert Uger, PhD

Chief Scientific Advisor, SAB

Dr. Uger has spent 20+ years developing novel agents targeting the immune system. He began his industry career in cancer vaccine research with Aventis Pasteur, and then joined start-up Trillium Therapeutics as Director, Research & Development, later serving as Vice President, Research & Development, and then Chief Scientific Officer until the company was acquired by Pfizer in 2021 for $2.2B. At Trillium, Dr. Uger was responsible for the company’s scientific strategy and guided several compounds from concept to clinic. His expertise spans both innate and adaptive immunology, and he has overseen programs in the fields of immuno-oncology, autoimmunity and transplantation. He received his PhD in immunology from the University of Toronto.

Kai Wucherpfennig, MD, PhD

Scientific Advisor, SAB

Kai Wucherpfennig, MD, PhD

Scientific Advisor, SAB

Dr. Wucherpfennig is Professor and Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and Professor of Neurology at Harvard Medical School. His research focuses on the discovery of genes that control the activity of cytotoxic T cells in the tumor microenvironment drawing insights for the development of next-generation cancer immunotherapies. He has received a number of honors and awards, including his election as a Fellow in the American Society for the Advancement of Science, his election as a member of the Henry Kunkel Society at Rockefeller University, and his election as a member of the American Society for Clinical Investigation. Dr. Wucherpfennig serves as an advisor to a number of immuno-oncology companies and venture funds.

Dane Wittrup, PhD

Scientific Advisor, SAB

Dane Wittrup, PhD

Scientific Advisor, SAB

Dr. Wittrup is the Carbon P. Dubbs Professor of Chemical Engineering and Biological Engineering at the Massachusetts Institute of Technology, and the Associate Director of the Koch Institute for Integrative Cancer Research. From 1989-1999 he was Assistant Professor, Associate Professor, and then J. W. Westwater Professor of Chemical Engineering, Bioengineering, and Biophysics at the University of Illinois in Champaign/Urbana. Prof. Wittrup received a B.S. in Chemical Engineering Summa cum Laude in 1984 from the University of New Mexico, and a Ph.D. in Chemical Engineering from the California Institute of Technology in 1988 under the thesis direction of Prof. James Bailey. Following a year of postdoctoral research at Amgen (Thousand Oaks, CA), Dr. Wittrup joined the faculty at the University of Illinois. Wittrup’s research program is focused on protein engineering of biopharmaceutical proteins by directed evolution. Areas of interest include: pre-targeted radio-immunotherapy; biological response modification of EGFR; and immunotherapy of cancer via engineered cytokines and vaccines. Dr. Wittrup has received the following awards and honors recognizing his scholarship: the A. McLaren White Award, for First Prize in the National American Institute of Chemical Engineers Student Design Contest (1984); the Presidential Young Investigator Award of the National Science Foundation (1990-1995); the Allan P. Colburn Award of the American Institute of Chemical Engineers, for excellence in publications for an individual under the age of 35 (1998); the University of New Mexico College of Engineering Distinguished Young Alumnus Award (2000); the Dow Chemical Company Teaching Award(1989); the UIUC School of Chemical Sciences Award for Excellence in Teaching (1993); the UIUC College of Engineering Anderson Award for Undergraduate Advising (1991, 1994); the J.R. Mares Professorship (1999-2007); the C.P. Dubbs Professorship (2007-); induction as a Fellow of the American Institute of Medical and Biological Engineers (1999); induction as Fellow, American Association for the Advancement of Science (2011); and Member, National Academy of Engineering (2012). In 2007, Prof. Wittrup co-founded Adimab, Inc. and serves as CSO. In 2009, he co-founded Eleven Biotherapeutics, and serves on the Scientific Advisory Board. He also serves as an advisor to many additional biotech companies.

Investors

News

Contact

To learn more about current openings at DEM BioPharma, please email recruiting@dembiopharma.com

DEM BioPharma is currently located in Alexandria LaunchLabs, Cambridge, MA.